Why is BEQIA’s FDA goal date different from its possible U.S. launch date?
TAHO Pharmaceuticals’ apixaban oral film BEQIA had an FDA review goal date of April 22, 2027, as reported in Drugnews’s November 5, 2026 analysis. The BMS–Pfizer patent case is a separate constraint: a qualifying suit filed within 45 days of patent notice can stay final FDA approval for up to 30 months. Neither interval establishes BEQIA’s actual launch date.
| Measure | Reported result | Basis |
|---|---|---|
| FDA review goal | April 22, 2027 | Company-announced target; not a launch commitment |
| Patent-litigation filing window | 45 days | After receipt of the relevant notice |
| Potential final-approval stay | Up to 30 months | Subject to statutory conditions and earlier terminating events |
The original article’s spring 2029 stay-expiry estimate depends on the notice date and legal outcome. It is not an established stay-expiry or commercial launch date.
Sources
Read the full analysis
TAHO Doubles in Two Weeks, but a Court Holds Its US Clock — 2026-11-05